Muscular Dystrophy Association's Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy
March 22, 2024
March 22, 2024
NEW YORK, March 22 (TNSres) -- The Muscular Dystrophy Association issued the following news release on March 21, 2024:
The Muscular Dystrophy Association's funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat (givinostat), a histone deacetylase (HDAC) inhibitor to treat children and adolescents living with Duchenne muscular dystrophy (DMD). This drug changes gene expression in cells by altering the three-dimensional fold . . .
The Muscular Dystrophy Association's funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat (givinostat), a histone deacetylase (HDAC) inhibitor to treat children and adolescents living with Duchenne muscular dystrophy (DMD). This drug changes gene expression in cells by altering the three-dimensional fold . . .